Covance-BML to Expand Clinical Trial Laboratory in Japan
PRINCETON, N.J., April 26, 2012 - Covance Inc., a leading
provider of drug development services, and BML, Inc., a
leading Japanese laboratory testing company, today
announced the expansion of the Covance-BML Clinical Trial
Laboratory (CB Trial Lab) in Kawagoe City, Saitama
Prefecture to enhance the capacity and capabilities in the
region. The companies, which opened the lab together in
2010 as part of a five-year agreement, will launch several
new expansion-related services this month.
"The expansion of the CB Trial Lab speaks to both the
success of our affiliation with BML and the growing drug
development relationships we have built with our clients in
Japan and across the Asia-Pacific region," said Jonathan
Koch, Global General Manager, Covance Central Laboratory
Services.
"This investment is an important step in growing our
relationship with Covance and allows us to offer clients a
wider range of services in an increasingly competitive
marketplace," said Kazuta Fukuda, President, BML.
The lab expansion includes increasing the size of the
original facility by 50 percent, while adding new testing
platforms, equipment and additional sample storage space.
Specifically, new laboratory testing platforms have been
added to enhance the capacity of the CB Trial Lab to manage
the growing demand for in-country testing services. These
new service offerings in the areas of immunoassay, flow
cytometry, and protein chemistry will speed results to
physicians conducting clinical trials for these critical
testing parameters.
The CB Trial Laboratory is accredited by the College of
American Pathologists (CAP), and maintains CDC lipid
certification as well as National Glycohemoglobin
Standardization Program (NGSP) Level 1 certification.
About Covance Inc.
Covance, with headquarters in Princeton, New Jersey, is one
of the world's largest and most comprehensive drug
development services companies with annual revenues greater
than $2 billion, global operations in more than 30
countries, and more than 11,000 employees worldwide.
Information on Covance's products and services, recent
press releases, and SEC filings can be obtained through its
website at www.covance.com.
About BML
BML, founded in 1955 and headquartered in Tokyo, Japan,
provides a wide range of laboratory testing from
biochemical and hematological tests to specialty tests such
as cellular immunological and DNA genetic analyses. BML
operates efficiently and economically using in-house
developed automation systems named "Frontier" and
"Symphony." In addition, BML has developed a proprietary
"Electronic Patients Charts" network system to support
total medical care, which is all-inclusive medical
information system for the next generation. For more
information about BML and its services, please visit BML's
website at http://www.bml.co.jp .
Statements contained in this press release, which are
not historical facts, are forward-looking statements
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such
forward-looking statements including the statements
contained herein regarding anticipated trends in the
Company's business are based largely on
management's expectations and are subject to and
qualified by risks and uncertainties that could cause
actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties
include, without limitation, competitive factors,
outsourcing trends in the pharmaceutical industry, trends
concerning clinical trials in Japan, levels of
industry research and development spending, the
Company's ability to continue to attract and retain
qualified personnel, the fixed price nature of contracts or
the loss of large contracts, and other factors described in
the Company's filings with the Securities and Exchange
Commission.
###
Recommend:
